Private corneal cross-linking (CXL) cost UK 2026

What is corneal cross-linking?

Corneal collagen cross-linking is a 60–90 minute outpatient procedure that strengthens a thinning, weakened cornea by creating new chemical bonds between collagen fibres in the corneal stroma. Riboflavin (vitamin B2) drops are applied to the cornea, then the eye is exposed to ultraviolet-A (UVA) light at 365 nm. The riboflavin acts as a photosensitiser: when it absorbs UVA energy it produces reactive oxygen species that form covalent cross-links between collagen molecules, increasing the cornea's biomechanical stiffness by approximately 300 per cent in the anterior 200 µm.

CXL is performed for two main indications: progressive keratoconus (an inherited corneal dystrophy that causes the cornea to thin and bulge into a cone shape, distorting vision) and post-refractive corneal ectasia (a rare complication of LASIK or PRK in which the cornea progressively weakens). Other indications include pellucid marginal degeneration and infectious keratitis (PACK-CXL).

CXL is approved by NICE (IPG466), supported by the Royal College of Ophthalmologists keratoconus pathway and recommended by the BCLA (British Contact Lens Association) consensus 2023–2025 update. It does not improve vision in most cases — its purpose is to halt progression so that vision can continue to be corrected with spectacles or specialist contact lenses, and so that the patient avoids corneal transplantation later.

UK 2026 corneal cross-linking price table

Typical 2026 self-pay fees observed across UK CQC-registered corneal centres (London, Manchester, Birmingham, Bristol, Edinburgh):

Quoted fees are typical 2026 totals; centres that publish unusually low fees (under £1,500 per eye) sometimes exclude tomography, follow-up imaging, theatre fees or post-op contact lenses — always request a written all-inclusive quote.

What is included in a private CXL fee?

A reputable UK 2026 corneal-specialist all-inclusive quote should cover:

• Consultant corneal surgeon consultation — history, refraction, slit-lamp examination, dry eye and tear-film assessment.
• Corneal tomography — Pentacam, Galilei or MS-39, with progression analysis if previous scans are available.
• Theatre fee, day-case admission and consumables — in a CQC-registered hospital or outpatient day-case unit.
• Riboflavin and UVA delivery system — iontophoresis device or KXL/Avedro CE-marked accelerated UVA system.
• Pre-operative anaesthetic drops, intra-operative medications and post-operative bandage contact lens.
• Post-operative drops — topical antibiotic, steroid and lubricant for 4–6 weeks.
• One year of follow-up — typically reviews at day 1, day 7 (BCL removal), 1, 3, 6 and 12 months with repeat tomography at 6 and 12 months to confirm stability.

Fees that exclude tomography, follow-up imaging or theatre are not directly comparable. Ask for an itemised quote and confirm whether out-of-hours care, repeat CXL within 12 months and corneal scarring management are included.

Cross-linking protocols: epi-off vs epi-on vs accelerated

1. Standard epi-off (Dresden) CXL

The original 2003 Dresden protocol: the corneal epithelium is removed mechanically over the central 9 mm, riboflavin 0.1 per cent in dextran is applied for 30 minutes, then the cornea is exposed to UVA at 3 mW/cm² for 30 minutes (5.4 J/cm² total). It remains the protocol with the strongest long-term evidence (10 year stability data) and is the BCLA-preferred protocol for progressive keratoconus. Recovery: 3–7 days of pain and blurred vision while the epithelium heals; visual recovery 1–3 months.

2. Accelerated epi-off CXL (KXL / Avedro)

Same biological effect compressed into a shorter UVA exposure: 9 mW/cm² for 10 minutes or 18 mW/cm² for 5 minutes, total 5.4 J/cm². Theatre time approximately 30 minutes shorter. Multiple randomised trials and the BCLA 2023 update confirm equivalent flattening and progression-arrest outcomes with the standard protocol over 3–5 years. Most UK private centres now offer accelerated as their default.

3. Epi-on (transepithelial) CXL

The epithelium is left intact and riboflavin is delivered through it, often using iontophoresis or a benzalkonium-chloride enhanced solution. Pain and visual blur are markedly reduced and recovery is 1–2 days. The biomechanical effect is smaller than epi-off, and the evidence base for halting progression (especially in younger patients with rapid progression) is weaker. Considered for: thin corneas (< 400 µm), patients who cannot tolerate epithelial removal, or maintenance treatments.

4. CXL plus (combined) protocols

For selected stable cases with adequate corneal thickness, CXL can be combined with topography-guided PRK ("Athens protocol") or intracorneal ring segments (ICRS) to flatten and regularise the cone in addition to halting progression. These combined protocols are not first-line for progressive keratoconus — the priority is to stop progression with CXL and consider visual rehabilitation procedures separately, once the cornea is stable.

NHS vs private corneal cross-linking

NHS England and the devolved UK nations fund corneal cross-linking when there is documented progression of keratoconus or corneal ectasia. Typical NHS funding criteria (adopted by most Integrated Care Boards and NHS trusts in 2024–2026):

• Documented progression on serial corneal tomography: increase of Kmax ≥ 1.0 D, or thinning of thinnest pachymetry by ≥ 30 µm, or refractive cylinder shift ≥ 1.0 D over 6–12 months.
• Minimum corneal thickness at the thinnest point ≥ 400 µm for standard epi-off (lower thresholds with hypotonic riboflavin).
• Age criteria — many NHS pathways prioritise patients under 30 (highest progression risk) but treat older patients with documented progression.
• No active corneal scarring or hydrops at the time of treatment.

The catch is the wait. UK 2024–2026 NHS waits for CXL are 12–52 weeks depending on the centre, and progression continues during the wait. The Royal College of Ophthalmologists and the BCLA both flag the risk of irreversible vision loss from delayed CXL. Self-pay private CXL can usually be done within 2–4 weeks of consultation, which for a young patient with rapid progression on tomography is often the deciding factor.

If you have keratoconus that is not progressing, NHS treatment is unlikely to be funded and private CXL is rarely indicated either — the right pathway is observation with annual tomography.

Private medical insurance cover for CXL

Cross-linking is generally covered by major UK private medical insurers when the same NHS criteria for documented progression are met:

• Bupa — covers CXL with corneal-specialist referral and documented progression; pre-authorisation required.
• AXA Health (PPP) — covers CXL with documented progression; tomography evidence required.
• Aviva — covers CXL on most plans; check whether keratoconus is included as a chronic condition under your specific policy.
• Vitality Health — covers CXL with corneal-specialist referral.
• WPA — covers CXL with documented progression on tomography.
• Cigna, Allianz, Healix — usually covered with pre-authorisation.

Practical tips: ask your corneal surgeon's secretary to send a pre-authorisation letter that explicitly references documented progression with tomography numbers, NICE IPG466 and the Royal College of Ophthalmologists keratoconus pathway. This is the most common way claims are approved.

Paediatric and adolescent CXL

Children and teenagers with keratoconus progress fastest — up to 88 per cent show progression within a year in some series. UK practice is to treat any progression at any age; the historical caution about treating under 18s has been abandoned by the Royal College of Ophthalmologists and BCLA. Paediatric pathways:

• NHS — tertiary paediatric ophthalmology and corneal services; usually treated under general anaesthetic in children under 14.
• Private — UK 2026 paediatric CXL costs £2,500–£4,500 per eye including general anaesthesia where required; both eyes typically £4,800–£7,500.

Bilateral simultaneous CXL is sometimes considered in children to minimise general-anaesthetic exposures, with appropriate consent and increased post-operative observation.

Risks and what can go wrong

Modern CXL has a strong long-term safety profile. Specific risks (typical incidence in UK 2026 corneal-centre audits):

• Pain and blurred vision in the first 5–7 days — expected with epi-off; markedly reduced with epi-on.
• Corneal haze — transient anterior stromal haze in ~50 per cent of epi-off cases; usually resolves over 6–12 months. Persistent visually significant haze 1–3 per cent.
• Sterile infiltrates — ~1–2 per cent; treated with topical steroid.
• Microbial keratitis — rare (< 0.5 per cent); treated with intensive topical antibiotics.
• Endothelial damage — very rare with thinnest pachymetry ≥ 400 µm; rationale for the 400 µm threshold and hypotonic riboflavin protocols below it.
• Re-progression requiring repeat CXL — 3–5 per cent at 5–10 years; commoner in young patients with high baseline Kmax.
• Refractive shift — small (~0.5–1.0 D flattening of Kmax) is expected and usually beneficial.

Sight-threatening complications are uncommon. The dominant risk is doing nothing — allowing progressive keratoconus to advance to corneal hydrops or to a stage where penetrating or deep anterior lamellar keratoplasty (PK / DALK) is required.

Recovery: what to expect after CXL

• Day 0 — surgery day. 60–90 minute outpatient procedure under topical anaesthetic. Bandage contact lens fitted. Mild ache, light sensitivity. Take the rest of the day off; arrange transport home.
• Days 1–5. Pain peaks at 24–48 hours after epi-off CXL; controlled with paracetamol, codeine if needed, and lubricant drops. Light sensitivity; sunglasses indoors and outdoors. Vision is blurred.
• Day 5–7. Bandage contact lens removed once epithelium has healed. Topical antibiotic stopped, topical steroid continued for 4–6 weeks tapering.
• Weeks 2–4. Vision continues to improve but remains slightly hazier than baseline.
• Months 1–3. Vision typically returns to within 1 line of pre-CXL best-corrected acuity. Specialist contact-lens refit can be planned at 8–12 weeks (usually scleral or rigid-gas-permeable lenses).
• 6 months and 12 months. Repeat tomography to confirm stability. Most patients show 0.5–1.5 D of Kmax flattening.
• Long-term. Annual tomography for life is recommended to detect re-progression early.

How to choose a CXL surgeon (UK 2026)

Cross-linking is technically straightforward but the surrounding decision-making (which protocol, when to combine with PRK or ICRS, when to repeat) is the part that needs a corneal subspecialist. Look for:

• GMC specialist register in Ophthalmology with a corneal/external-disease subspecialty fellowship.
• UKISCRS or BSCCS membership (UK and Ireland Society of Cataract and Refractive Surgeons; British Society for Corneal and Contact Lens Specialists).
• CQC-registered hospital or day-case unit with published outcomes data.
• Pentacam / Galilei / MS-39 tomography in-house with progression analysis.
• Audited outcomes — the surgeon should be willing to share their CXL stability rate at 12 months, complication rate and re-progression rate.
• Specialist contact-lens service (or close referral pathway) for post-CXL scleral / RGP fitting.
• Multi-modality offering — CXL alone, CXL plus PRK, CXL plus ICRS, and direct access to corneal transplantation if needed.

Avoid centres that quote unusually low fees without itemising what is included, that propose CXL without serial tomography evidence of progression, or that recommend bilateral simultaneous CXL in adults as routine.

Frequently asked questions

How much does private corneal cross-linking cost in the UK in 2026?

UK 2026 private corneal cross-linking typically costs £1,800–£3,500 per eye all-inclusive, with most London corneal-specialist centres charging £2,200–£2,950 per eye. Both eyes (sequential) typically cost £3,400–£6,500. The fee should include corneal consultation, tomography, theatre, surgeon fee, riboflavin, UVA, post-operative bandage contact lens, drops and one year of follow-up.

Does the NHS pay for cross-linking?

Yes — for documented progression. UK 2026 NHS funding criteria across most Integrated Care Boards require documented progression on serial tomography: Kmax increase ≥ 1.0 D, thinnest pachymetry decrease ≥ 30 µm, or refractive cylinder shift ≥ 1.0 D over 6–12 months, with thinnest corneal thickness ≥ 400 µm and no active scarring. Typical NHS waits are 12–52 weeks, during which progression continues.

Will my insurance cover CXL?

Major UK insurers (Bupa, AXA, Aviva, Vitality, WPA) usually cover CXL for documented progressive keratoconus or post-LASIK ectasia with corneal-specialist referral and pre-authorisation. The pre-authorisation letter should reference NICE IPG466, the documented progression on tomography, and the corneal subspecialty referral. Cosmetic or "preventive" CXL without progression is not insurer-funded.

Will CXL improve my vision?

CXL is designed to halt progression, not reverse keratoconus. Most patients see a small flattening of Kmax (0.5–1.5 D) and a small improvement in best-spectacle-corrected vision over 6–12 months, but visual rehabilitation usually still requires specialist contact lenses. To improve vision more, CXL can be combined with topography-guided PRK ("Athens protocol") or intracorneal ring segments in selected cases.

How painful is CXL recovery?

Standard epi-off CXL is moderately painful for 24–48 hours; pain settles over 5–7 days as the epithelium heals. Pain is controlled with paracetamol, codeine if required, lubricant drops and a bandage contact lens. Epi-on (transepithelial) CXL is markedly less painful but the long-term progression-arrest evidence is weaker. Most adults are back to office work or study at 7–10 days.

How long does the effect of CXL last?

Long-term studies (10 to 15 year follow-up) show stability in 95–97 per cent of treated eyes. Approximately 3–5 per cent re-progress and require a repeat CXL, more commonly in young patients with high baseline Kmax. Annual corneal tomography for life is recommended to detect re-progression early.

Is accelerated CXL as good as standard (Dresden) CXL?

Yes for most cases. Multiple randomised trials and the BCLA 2023 consensus update show equivalent flattening and progression-arrest at 3–5 years for accelerated epi-off CXL (9 mW/cm² for 10 minutes, total 5.4 J/cm²) compared with standard Dresden epi-off CXL. Most UK private corneal centres offer accelerated as their default protocol.

Can both eyes be done on the same day?

Same-day bilateral CXL is generally not recommended in adults: post-operative pain, light sensitivity and visual blur affect both eyes simultaneously and the (very small) risk of microbial keratitis is bilateral. Most UK centres treat one eye, then the second 4–12 weeks later. Bilateral same-day CXL is sometimes considered in children to minimise general-anaesthetic exposures, with appropriate consent.

What is the minimum corneal thickness for CXL?

Standard epi-off CXL with isotonic riboflavin requires a thinnest corneal thickness of at least 400 µm after epithelial removal to protect the corneal endothelium from UVA exposure. Below 400 µm, hypotonic riboflavin (which transiently swells the cornea) or "individualised fluence" protocols extend treatment to thinner corneas; in very thin corneas (under 350 µm) deep anterior lamellar keratoplasty (DALK) may be the better option.

Can I have LASIK or PRK after CXL?

Standard LASIK is not advised on a previously cross-linked, keratoconic cornea because the cornea is too thin and biomechanically abnormal. Topography-guided PRK can be considered in selected stable, thicker eyes 12 months or more after CXL ("Athens protocol"). For visual rehabilitation, specialist scleral or rigid-gas-permeable contact lenses, or intracorneal ring segments, are the more common pathway.

How do I know if my keratoconus is progressing?

Progression is defined on serial corneal tomography (Pentacam, Galilei or MS-39): an increase in Kmax of 1.0 D or more, a decrease in thinnest pachymetry of 30 µm or more, or a refractive cylinder shift of 1.0 D or more over 6–12 months. Symptoms (more frequent prescription changes, worsening contact-lens fit) are suggestive but not diagnostic. A formal progression analysis from your corneal surgeon is the right way to decide whether CXL is needed now.

Sources & methodology

• NICE Interventional Procedures Guidance IPG466. Corneal collagen cross-linking for keratoconus, keratectasia and corneal melting.
• Royal College of Ophthalmologists. Keratoconus and corneal cross-linking commissioning guidance, 2023–2024.
• British Contact Lens Association (BCLA). Consensus statement on corneal cross-linking, 2023 update.
• Glaukos / Avedro. KXL System and Photrexa labelling and clinical trial outcomes.
• NHS England. Specialised commissioning manual: ophthalmology, 2024.
• UKISCRS & BSCCS keratoconus and refractive surgery audits, UK 2024–2026.
• Care Quality Commission (CQC) registered private ophthalmic centre published self-pay tariffs, 2024–2026.

Pricing reflects 2026 published self-pay quotes from CQC-registered UK corneal centres in London, Manchester, Birmingham, Bristol and Edinburgh. Reviewed by a UK GMC-registered consultant corneal surgeon. This article is for information only and is not a substitute for personalised medical advice. The right cross-linking pathway depends on your tomography findings and rate of progression.